News Breaks |
|
|
| September 21, 2012 |
| 12:18 EDT |  | HALO, ORCL, MCD, KORS, KBH, COV, VVUS, VPHM, DRI, TXN, BTH | On The Fly: Midday Wrap
Stocks on Wall Street were higher at midday amid optimism that Spain may be moving closer to asking for additional aid. Stock futures reversed and closed the premarket trading session higher. The futures action led to a slightly higher open for the broader market, as traders prepared for options expiration. The averages remained higher throughout the morning, though they moved in a narrow range. The lack of movement is in stark contrast to options expirations in years past, which were typically marked by elevated volatility... ECONOMIC EVENTS: In the U.S., the economic calendar was light. In Europe, reports indicated that Spain is weighing more aggressive reform measures in anticipation of a bailout deal... COMPANY NEWS: McDonald’s (MCD), Texas Instruments (TXN) and Covidien (COV) all announced double-digit percentage increases to their quarterly dividends after the closing bell yesterday... Among those reporting earnings after the bell yesterday and before the open today, Oracle (ORCL), Darden (DRI) and KB Home (KBH) all advanced... MAJOR MOVERS: Among the notable gainers were Halozyme (HALO), up 30%, and ViroPharma (VPHM), up 8%, after the FDA gave guidance enabling ViroPharma to resume clinical studies of a drug it is developing that uses Halozyme technology for delivery. Also higher were shares of Michael Kors (KORS), which rose nearly 5% after the company raised its view for its quarterly and full year profit. Among the noteworthy losers was Blyth (BTH), down another 15% following a slide yesterday after Moody's said it has reduced its outlook for the company. Also lower were shares of VIVUS (VVUS), which fell 11% after the company said a European regulatory committee would likely recommend that its Qsiva anti-obesity drug not be approved... INDICES: Near noon, the Dow was up 33.07, or 0.24%, to 13,630.00; the Nasdaq was up 13.89, or 0.44%, to 3,189.85; and the S&P 500 was up 3.84, or 0.26%, to 1,464.10. |
|
|
News For MCD;TXN;COV;ORCL;DRI;KBH;HALO;VPHM;KORS;BTH;VVUS From The Last 14 Days Check below for free stories on MCD;TXN;COV;ORCL;DRI;KBH;HALO;VPHM;KORS;BTH;VVUS the last two weeks. |
|
|
| May 17, 2013 |
| 06:15 EDT |  | MCD | McDonald's to reduce its menu, Bloomberg reports
 Subscribe for More Information |
|
| 06:09 EDT |  | KORS | Citi recommends Michael Kors ahead of Q4 results
Subscribe for More Information |
|
| May 16, 2013 |
| 08:42 EDT | | HALO | Halozyme data favorable, says JMP Securities
JMP Securities was highly encouraged by data from a Phase I trial of Halozyme's PEGPH20 in pancreatic cancer, as the drug generated response rates that were significantly higher than competing drugs, according to the firm. JMP Securities raised its target on Halozyme to $12 from $10 and reiterates an Outperform rating on the shares. |
|
| 07:28 EDT |  | COV | I/O Central to host a conference
Subscribe for More Information |
|
| 07:26 EDT | | TXN | JPMorgan to host a conference
41st Annual Global Technology, Media & Telecom Conference is being held in Boston on May 14-16 with webcasted company presentations to begin on May 16 at 8 am; not all company presentations may be webcasted. Webcast Link |
|
| May 15, 2013 |
| 18:07 EDT |  | HALO | Halozyme to present new PEGPH20 phase 1b trial data
Halozyme Therapeutics announced that clinical data from a phase 1b trial of PEGPH20, an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology annual meeting. In this phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate was 42%as assessed by independent review at therapeutic dose levels of PEGPH20. Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Based on the magnitude of response and safety observed in the Phase 1b study, Halozyme announced in April the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. |
|
| 11:48 EDT | | ORCL | Appaloosa reports new stakes in Comcast, Ashland, sells Oracle
David Tepper's Appaloosa in its quarterly filing report new positions in Comcast (CMCSA), Prudential (PRU), Hess Corp. (HES), Check Point (CHKP), KBR (KBR) and Ashland (ASH). The fund sold its stakes in Oracle (ORCL) and Noble Corp. (NE). Appaloosa's top position is in Citigroup (C), with a stake worth over $376.9M. |
|
| 11:28 EDT | | ORCL | David Tepper's Appaloosa liquidates stake in Oracle
Subscribe for More Information |
|
| 10:13 EDT |  | HALO | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:01 EDT | | KORS | Michael Kors recommended ahead of Q4 results at Piper Jaffray
Subscribe for More Information |
| |
| May 14, 2013 |
| 16:08 EDT | | HALO | Halozyme initiated with an Overweight at Piper Jaffray
Subscribe for More Information |
|
| 10:01 EDT |  | KBH, VVUS | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital. |
|
| 08:04 EDT | | KBH | KB Home downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information |
|
| 07:33 EDT | | VVUS | VIVUS downgraded to Neutral from Buy at Lazard Capital
Subscribe for More Information |
|
| May 13, 2013 |
| 09:37 EDT |  | KORS | Michael Kors rises after addition to Best Ideas List at Morgan Stanley
Subscribe for More Information |
|
| 07:41 EDT | | VVUS | VIVUS mails letter to stockholders providing business update
Subscribe for More Information |
|
| 07:31 EDT | | ORCL | Brightcover to host a conference
3rd Annual Brightcove PLAY Global Customer Conference is being held in Boston on May 13-15. |
|
| 07:30 EDT | | TXN | TechConnect to host a summit
2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. |
|
| 07:29 EDT | | KORS | Michael Kors added to Best Ideas List at Morgan Stanley
Subscribe for More Information |
|
| May 10, 2013 |
| 14:52 EDT | | ORCL | Market poised to end week higher as tech helps lead advance
Subscribe for More Information |
| |
|
|
|
|
